Senti Biosciences Enters Material Definitive Agreement
Ticker: SNTI · Form: 8-K · Filed: Jul 16, 2024 · CIK: 1854270
Sentiment: neutral
Topics: material-agreement
TL;DR
Senti Bio signed a big deal, details TBD.
AI Summary
On July 16, 2024, Senti Biosciences, Inc. filed an 8-K to report the entry into a material definitive agreement. The filing does not disclose specific details of the agreement or any involved parties.
Why It Matters
This filing indicates a significant new contract or partnership for Senti Biosciences, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the material definitive agreement.
Key Players & Entities
- Senti Biosciences, Inc. (company) — Registrant
- July 16, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Senti Biosciences?
The filing does not specify the nature of the material definitive agreement.
Who are the other parties involved in this material definitive agreement?
The filing does not disclose the names of the other parties involved in the agreement.
What is the effective date of this material definitive agreement?
The filing states the date of the earliest event reported is July 16, 2024, which is presumed to be the effective date or announcement date.
Does this agreement involve any financial commitments or transactions?
The filing does not provide details on any financial commitments or transactions related to the agreement.
Where can more information about this material definitive agreement be found?
Further details may be available in exhibits attached to this 8-K filing, which are not fully detailed in the provided text.
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-07-16 16:04:29
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SNTI The Nasdaq Capital Marke
- $50,000,000 — LLC in connection with its outstanding $50,000,000 equity facility to sell shares of the C
Filing Documents
- snti-20240716.htm (8-K) — 29KB
- a202407168kex101.htm (EX-10.1) — 574KB
- 0001854270-24-000091.txt ( ) — 824KB
- snti-20240716.xsd (EX-101.SCH) — 2KB
- snti-20240716_lab.xml (EX-101.LAB) — 22KB
- snti-20240716_pre.xml (EX-101.PRE) — 13KB
- snti-20240716_htm.xml (XML) — 3KB
01. Entry Into a Material Definitive Agreement
Item 1.01. Entry Into a Material Definitive Agreement. On July 16, 2024, Senti Biosciences, Inc. (the " Company ") entered into an amended and restated ChEF purchase agreement (the " A&R Purchase Agreement ") with Chardan Capital Markets LLC in connection with its outstanding $50,000,000 equity facility to sell shares of the Company's common stock, par value $0.0001 per share, to update the volume weighted average price purchase mechanics of the equity facility to permit Intraday VWAP Purchases (as defined in the A&R Purchase Agreement). The foregoing description of the A&R Purchase Agreement is a summary only and is qualified in its entirety by the full text of the A&R Purchase Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1# Amended and Restated ChEF Purchase Agreement, by and between Chardan Capital Markets LLC and Senti Biosciences, Inc., dated July 1 6 , 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) # Portions of schedules and exhibits to the agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SENTI BIOSCIENCES, INC. Date: July 16, 2024 By: /s/ Timothy Lu, M.D., Ph.D. Name: Timothy Lu, M.D., Ph.D. Title: Chief Executive Officer